SynthesisFrontiers in epigenetics and epigenomics2026
Environmental epigenetic modifiers in neurodegenerative diseases: a systematic review of epigenomic mechanisms and therapeutic targets.
Synthesis in Frontiers in epigenetics and epigenomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Environmental contaminants and neurotoxicants are becoming more widely acknowledged as major causes of neurodegenerative illnesses due to systemic biological disruption including oxidative stress, mitochondrial dysfunction, chronic neuroinflammation, and chromatin remodeling-associated epigenetic dysregulation epigenetic modification. According to new research, exposures to heavy metals, gaseous pollutants, particulate matter, and synthetic neurotoxicants alter gene-regulatory networks and accelerate neurodegenerative processes. Objective: With an emphasis on molecular mechanisms, developmental neurotoxicity, and translational pathways connecting environmental exposures with epigenomic changes and neurological outcomes, the goal of this systematic review is to compile the most recent data on environmental epigenetic modifiers in neurodegenerative diseases. Method: Using structured searches across major biomedical databases, the review was carried out in accordance with PRISMA principles. A multistage selection procedure was used to evaluate studies that addressed environmental neurotoxicants, epigenetic processes (DNA methylation, histone modification, and non-coding RNAs), and neurodegenerative consequences. To find common routes and life-course exposure effects, relevant experimental, epidemiological, mechanistic, and translational data were qualitatively summarized. Results: The findings of the included research show that exposure to the environment causes oxidative stress, mitochondrial dysfunction, neuroinflammation, and chromatin remodeling. These effects result in alterations in histone acetylation, DNA methylation patterns, and dysregulated expression of microRNAs. Amyloidogenic signaling, synaptic dysfunction, and neuronal death were consistently linked to both chemical and particulate matter neurotoxicants. Furthermore, early environmental stressors create long-term epigenetic programming that heightens vulnerability to eventual neurodegenerative pathology, according to developmental exposure models. Conclusion: An important link between the exposome and the risk of neurodegenerative diseases is represented by environmental epigenetic modifiers. Epigenetic pathways including histone acetylation imbalance, microRNA-mediated regulation (e.g., miR-574-5p), and DNA methylation changes emerge as potential biomarkers and therapeutic targets. Future research should prioritizemulti-omics techniques, harmonized exposure assessment, and longitudinal human investigations to advance precision prevention and intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.